Corbus Pharmaceuticals Reports 2015 Financial Results and Provides 2016...
NORWOOD, MA--(Marketwired - March 29, 2016) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic,...
View ArticlePROMETIC REPORTS ITS 2015 FOURTH QUARTER AND YEAR END HIGHLIGHTS AND...
(Source: ProMetic Life Sciences Inc) • Clinical efficacy in humans confirmed for PBI-4050 • ProMetic's plasminogen phase 2/3 clinical trial initiated • ProMetic's IVIG phase 3 clinical trial initiated...
View ArticleTobira Therapeutics and Dong-A ST Enter Into License Agreements for...
SOUTH SAN FRANCISCO, Calif. and SEOUL, South Korea, April 11, 2016 /PRNewswire/ -- Tobira Therapeutics, Inc. (NASDAQ: TBRA) and Dong-A ST Co., Ltd. (170900: Korea SE), today announced that the...
View ArticleIonis Pharmaceuticals Advances Nusinersen in the Ongoing SHINE Study in...
(Source: Isis Pharmaceuticals Inc) CARLSBAD, Calif., March 31, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it has earned a milestone payment of $7.5 million...
View ArticleOhr Pharmaceutical, Inc. Announces SPA Agreement with US FDA and Initiation...
(Source: OHR Pharmaceutical Inc) First of Two Planned Phase III Trials Initiated to Evaluate Squalamine (OHR-102) Combination Therapy for the Treatment of Wet AMD NEW YORK, March 29, 2016 (GLOBE...
View ArticleViking Therapeutics Presents Positive Phase 1b Clinical Data on VK2809 in...
SAN DIEGO, April 11, 2016 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or...
View ArticleBiota Pharmaceuticals, Inc. Announces Name Change to Aviragen Therapeutics,...
(Source: Biota Pharmaceuticals Inc) ATLANTA, April 12, 2016 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) today announced that the Company has changed its name to Aviragen Therapeutics,...
View ArticlePROMETIC CONFIRMS PBI-4050’S ANTI-FIBROTIC EFFECT IN NASH MODEL AND ON HUMAN...
(Source: ProMetic Life Sciences Inc) Down regulation of fibrotic biomarkers in human hepatic stellate cells (HHSC); key cells involved in liver fibrosis. PBI-4050 significantly reduces liver fibrosis...
View ArticleAgios Announces Initiation of Phase 1/2 Frontline Combination Study of AG-221...
CAMBRIDGE, Mass., March 30, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the...
View ArticleNordic Nanovector to present at the Swiss Biotech Day on 12 April 2016...
(Source: Nordic Nanovector ASA) Oslo, Norway, 7 April 2016 Nordic Nanovector ASA (OSE: NANO), a company focusing on the development and commercialisation of novel targeted therapeutics in haematology...
View ArticleAllergan and Heptares Announce Global R&D and Commercialization Partnership...
(Source: Allergan plc) DUBLIN and LONDON, April 6, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Heptares Therapeutics, the wholly-owned subsidiary of...
View ArticleAllergan and Heptares Announce Global R&D and Commercialization Partnership...
DUBLIN and LONDON, April 6, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation...
View ArticleMorphoSys and Galapagos Initiate Phase 1 Study in Joint Antibody Program...
(Source: MorphoSys AG) April 07, 2016 / 8:30 am, CEST MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) and Galapagos NV (Euronext & NASDAQ: GLPG) announced today that dosing of...
View ArticleAgios Announces Initiation of Phase 1/2 Frontline Combination Study of AG-221...
(Source: Agios Pharmaceuticals Inc) CAMBRIDGE, Mass., March 30, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic...
View ArticleRXi Pharmaceuticals to Present at the Association for Research in Vision and...
MARLBOROUGH, Mass., April 18, 2016 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that...
View ArticleRXi Pharmaceuticals Reports Fourth Quarter and Year End 2015 Financial...
MARLBOROUGH, Mass., March 30, 2016 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that...
View ArticleRXi Pharmaceuticals Strengthens Intellectual Property Portfolio for Dermal...
MARLBOROUGH, Mass., March 31, 2016 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that...
View ArticlePCI Biotech to present at BIO-Europe Spring 2016 (PCI Biotech Holding ASA)
(Source: PCI Biotech Holding ASA) Posted on Apr 5, 2016 Press release, Oslo, April 5, 2016 - PCI Biotech will present at BIO-Europe Spring 2016 on Tuesday, April 5, 2016 at 10:45 a.m. local time at...
View ArticleGilead Sciences Announces Acquisition of Nimbus Therapeutics’ Acetyl-CoA...
(Source: Gilead Sciences Inc) FOSTER CITY, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 4, 2016-- Gilead Sciences, Inc. (NASDAQ:GILD) and Nimbus Therapeutics, LLC today announced that the...
View ArticleLuye Announces 2015 Annual Results (Luye Pharma Group Ltd)
(Source: Luye Pharma Group Ltd) [30, March 2016, Hong Kong] Luye Pharma Group Ltd. (the 'Company', to-gether with its subsidiaries, 'Luye', stock code: 2186.HK), a leading innovative pharmaceutical...
View Article